Angina pectoris in coronary heart disease is a common complex polygenic disease. Its morbidity and mortality have been increasing year by year

threatening human health seriously. Despite of multiple treatment options including myocardial revascularization

pharmacotherapy (as organic nitrates

b-blockers

calcium channel antagonists)

preventive therapies (lifestyle interventions

risk factor modification) and several alternative procedures

some patients still experience cardiovascular events and their quality of life is impaired. In China

traditional Chinese medicine (TCM) has been widely used to treat cardiovascular diseases for a long time. With the development of the pharmaceutical technology of TCM

more and more TCM injections have been used for the treatment of angina pectoris. Danhong injection (DHI)

which is typically used to resolve blood stasis

has been widely used in clinical practice for the treatment of angina pectoris in China. Several clinical studies have also demonstrated that Danhong injection is an effective and safe option for the treatment of angina pectoris in coronary heart disease. However

there are still some problems existing in the clinical and basic researches of DHI treatment of angina pectoris in coronary heart disease. Firstly

most clinical trials were low-quality studies. There were several drawbacks in the methodological quality of most original clinical trials. Therefore

well-designed randomized controlled trials are needed in the future. Secondly

the underlying pharmacological mechanisms of DHI on angina pectoris in coronary heart disease remain unclear. Therefore

this modular pharmacology-based analysis can provide new insight into the multi-target mechanisms of pharmacological action in DHI treatment for angina pectoris in coronary heart disease.